Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
5,400
Employees5,400
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
5,400
Employees5,400

PODD Key Statistics

Market cap
10.73B
Market cap10.73B
Price-Earnings ratio
36.05
Price-Earnings ratio36.05
Dividend yield
Dividend yield
Average volume
1.41M
Average volume1.41M
High today
$156.89
High today$156.89
Low today
$152.41
Low today$152.41
Open price
$154.55
Open price$154.55
Volume
947.67K
Volume947.67K
52 Week high
$354.88
52 Week high$354.88
52 Week low
$145.59
52 Week low$145.59

Stock Snapshot

The current Insulet(PODD) stock price is $154.87, with a market capitalization of 10.73B. The stock trades at a price-to-earnings (P/E) ratio of 36.05.

On 2026-05-25, Insulet(PODD) stock traded between a low of $152.41 and a high of $156.89. Shares are currently priced at $154.87, which is +1.6% above the low and -1.3% below the high.

The Insulet(PODD)'s current trading volume is 947.67K, compared to an average daily volume of 1.41M.

During the past year, Insulet(PODD) stock moved between $145.59 at its lowest and $354.88 at its peak.

During the past year, Insulet(PODD) stock moved between $145.59 at its lowest and $354.88 at its peak.

PODD News

MarketWatch 3d
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch

...

Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
TipRanks 4d
Insulet Shareholders Approve Proposals at Annual Meeting

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, person...

TipRanks 5d
Insulet assumed with an Outperform at William Blair

William Blair assumed coverage of Insulet (PODD) with an Outperform rating. The firm believes the shares are pricing in a lot of investor concerns relating to i...

Analyst ratings

86%

of 28 ratings
Buy
85.7%
Hold
10.7%
Sell
3.6%

More PODD News

TipRanks 6d
Insulet Earnings Call Highlights Strong Growth and Outlook

Insulet ((PODD)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful in...

Simply Wall St 6d
What Insulet's Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders

In early May 2026, Insulet Corporation reported past first-quarter results showing US$761.7 million in revenue and US$91.1 million in net income, confirmed and...

What Insulet's Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.